Table 3.
FDG PET/CT and FDG-PET/MRI in management of cervical cancer (CC).
| Domain | Imaging | References | Sensitivity | Specificity | Accuracy | ||
|---|---|---|---|---|---|---|---|
| Staging or diagnosis of primary CC | FDG PET/CT | [107,108,109,112,113,114,115,117,118] | FDG PET/CT | Staging | 0–53.5% | 81.87–100% | 96% |
| Diagnosis | 67–86.66% | 44.44–91% | 76.92–95.45% | ||||
| FDG-PET/MRI | [110,111] | FDG-PET/MRI | Staging | 77–91% | 90–94% | 87–93% | |
| FDG-PET/MRI vs. FDG PET/CT | [106] | Diagnosis | 64.9% | - | 78.5% | ||
| Treatment prognosis and prediction of response to treatment of CC | FDG PET/CT | [122,123,124,125,126,127,128,129] | 20–94.8% | 62–100% | 89% | ||
| Diagnosis or prediction of recurrence of CC | FDG PET/CT | [132,133,134] | 90.3% | 81.0% | 86.5% | ||
| Detection or prediction of CC metastasis | FDG PET/CT | [136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156] | 28.6–92.8% | 58.33–98.8% | 65.1–99.3% | ||
| Prognostic value and prediction of survival of CC | FDG PET/CT | [160,161,162,163,164,165] | - | - | - | ||